|
1
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Camejo N, Castillo C, Alonso R, Correa F,
Rivero E, Mezquita C, Rosich A, Dellacasa F, Silveira L and Delgado
L: Effectiveness of Trastuzumab for Human Epidermal Growth Factor
Receptor 2-Positive Breast Cancer in a Real-Life Setting: One
Decade of Experience Under National Treatment Coverage Regulations.
JCO Glob Oncol. 6:217–223. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Diaby V, Tawk R, Sanogo V, Xiao H and
Montero AJ: A review of systematic reviews of the
cost-effectiveness of hormone therapy, chemotherapy, and targeted
therapy for breast cancer. Breast Cancer Res Treat. 151:27–40.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Geng SQ, Alexandrou AT and Li JJ: Breast
cancer stem cells: Multiple capacities in tumor metastasis. Cancer
Lett. 349:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Samanta D, Gilkes DM, Chaturvedi P, Xiang
L and Semenza GL: Hypoxia-inducible factors are required for
chemotherapy resistance of breast cancer stem cells. Proc Natl Acad
Sci USA. 111:E5429–E5438. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li X, Lewis MT, Huang J, Gutierrez C,
Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC,
et al: Intrinsic resistance of tumorigenic breast cancer cells to
chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao J, Liu J, Xie F, Lu Y, Yin C and Shen
X: Co-Delivery of Docetaxel and Salinomycin to Target Both Breast
Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles. Int J
Nanomedicine. 14:9199–9216. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andrews P, Thyssen J and Lorke D: The
biology and toxicology of molluscicides, Bayluscide. Pharmacol
Ther. 19:245–295. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen B, Wei W, Ma L, Yang B, Gill RM, Chua
MS, Butte AJ and So S: Computational Discovery of Niclosamide
Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of
Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting
Cell Division Cycle 37 Signaling. Gastroenterology. 152:2022–2036.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Al-Hadiya BM: Niclosamide: Comprehensive
profile. Profiles Drug Subst Excip Relat Methodol. 32:67–96. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu J, Chen X, Ward T, Pegram M and Shen
K: Combined niclosamide with cisplatin inhibits
epithelial-mesenchymal transition and tumor growth in
cisplatin-resistant triple-negative breast cancer. Tumour Biol.
37:9825–9835. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J, Chen X, Ward T, Mao Y, Bockhorn J,
Liu X, Wang G, Pegram M and Shen K: Niclosamide inhibits
epithelial-mesenchymal transition and tumor growth in
lapatinib-resistant human epidermal growth factor receptor
2-positive breast cancer. Int J Biochem Cell Biol. 71:12–23. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taliaferro-Smith L, Oberlick E, Liu T,
McGlothen T, Alcaide T, Tobin R, Donnelly S, Commander R, Kline E,
Nagaraju GP, et al: FAK activation is required for IGF1R-mediated
regulation of EMT, migration, and invasion in mesenchymal triple
negative breast cancer cells. Oncotarget. 6:4757–4772. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schieber MS and Chandel NS: ROS links
glucose metabolism to breast cancer stem cell and EMT phenotype.
Cancer Cell. 23:265–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu L, Dong J, Wang L, Xia Q, Zhang D, Kim
H, Yin T, Fan S and Shen Q: Activation of STAT3 and Bcl-2 and
reduction of reactive oxygen species (ROS) promote radioresistance
in breast cancer and overcome of radioresistance with niclosamide.
Oncogene. 37:5292–5304. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu Y, Zuo W, Chen L, Bian S, Jing J, Gan
C, Wu X, Liu H, Su X, Hu W, et al: Repurposing of the
anti-helminthic drug niclosamide to treat melanoma and pulmonary
metastasis via the STAT3 signaling pathway. Biochem Pharmacol.
169:1136102019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Osada T, Chen M, Yang XY, Spasojevic I,
Vandeusen JB, Hsu D, Clary BM, Clay TM, Chen W, Morse MA, et al:
Antihelminth compound niclosamide downregulates Wnt signaling and
elicits antitumor responses in tumors with activating APC
mutations. Cancer Res. 71:4172–4182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Londoño-Joshi AI, Arend RC, Aristizabal L,
Lu W, Samant RS, Metge BJ, Hidalgo B, Grizzle WE, Conner M,
Forero-Torres A, et al: Effect of niclosamide on basal-like breast
cancers. Mol Cancer Ther. 13:800–811. 2014. View Article : Google Scholar
|
|
21
|
You S, Li R, Park D, Xie M, Sica GL, Cao
Y, Xiao ZQ and Deng X: Disruption of STAT3 by niclosamide reverses
radioresistance of human lung cancer. Mol Cancer Ther. 13:606–616.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo F, Luo M, Rong QX, Zhang H, Chen Z,
Wang F, Zhao HY and Fu LW: Niclosamide, an antihelmintic drug,
enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in
non-small cell lung cancer. J Immunother Cancer. 7:2452019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q,
Wei W, Zhang Y and Sun S: Breast cancer subtypes predict the
preferential site of distant metastases: A SEER based study.
Oncotarget. 8:27990–27996. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fillmore CM and Kuperwasser C: Human
breast cancer cell lines contain stem-like cells that self-renew,
give rise to phenotypically diverse progeny and survive
chemotherapy. Breast Cancer Res. 10:R252008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grimshaw MJ, Cooper L, Papazisis K,
Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou
J and Burchell JM: Mammosphere culture of metastatic breast cancer
cells enriches for tumorigenic breast cancer cells. Breast Cancer
Res. 10:R522008. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Levine AJ and Puzio-Kuter AM: The control
of the metabolic switch in cancers by oncogenes and tumor
suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alasadi A, Chen M, Swapna GVT, Tao H, Guo
J, Collantes J, Fadhil N, Montelione GT and Jin S: Effect of
mitochondrial uncouplers niclosamide ethanolamine (NEN) and
oxyclozanide on hepatic metastasis of colon cancer. Cell Death Dis.
9:2152018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lu J, Tan M and Cai Q: The Warburg effect
in tumor progression: Mitochondrial oxidative metabolism as an
anti-metastasis mechanism. Cancer Lett. 356 (2 Pt A):156–164. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park SJ, Shin JH, Kang H, Hwang JJ and Cho
DH: Niclosamide induces mitochondria fragmentation and promotes
both apoptotic and autophagic cell death. BMB Rep. 44:517–522.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Khanim FL, Merrick BA, Giles HV, Jankute
M, Jackson JB, Giles LJ, Birtwistle J, Bunce CM and Drayson MT:
Redeployment-based drug screening identifies the anti-helminthic
niclosamide as anti-myeloma therapy that also reduces free light
chain production. Blood Cancer J. 1:e392011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu K, Wang T, Li Y, Wang C, Wang X, Zhang
M, Xie Y, Li S, An Z and Ye T: Niclosamide induces apoptosis
through mitochondrial intrinsic pathway and inhibits migration and
invasion in human thyroid cancer in vitro. Biomed Pharmacother.
92:403–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu
L, Li D, Wang N, Zhang L, Zhu Y, et al: The anthelmintic drug
niclosamide induces apoptosis, impairs metastasis and reduces
immunosuppressive cells in breast cancer model. PLoS One.
9:e858872014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Duru N, Candas D, Jiang G and Li JJ:
Breast cancer adaptive resistance: HER2 and cancer stem cell
repopulation in a heterogeneous tumor society. J Cancer Res Clin
Oncol. 140:1–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Duru N, Fan M, Candas D, Menaa C, Liu HC,
Nantajit D, Wen Y, Xiao K, Eldridge A, Chromy BA, et al:
HER2-associated radioresistance of breast cancer stem cells
isolated from HER2-negative breast cancer cells. Clin Cancer Res.
18:6634–6647. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim JS, Kim HA, Seong MK, Seol H, Oh JS,
Kim EK, Chang JW, Hwang SG and Noh WC: STAT3-survivin signaling
mediates a poor response to radiotherapy in HER2-positive breast
cancers. Oncotarget. 7:7055–7065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chung SS, Giehl N, Wu Y and Vadgama JV:
STAT3 activation in HER2-overexpressing breast cancer promotes
epithelial-mesenchymal transition and cancer stem cell traits. Int
J Oncol. 44:403–411. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li G, Zhao L, Li W, Fan K, Qian W, Hou S,
Wang H, Dai J, Wei H and Guo Y: Feedback activation of STAT3
mediates trastuzumab resistance via upregulation of MUC1 and MUC4
expression. Oncotarget. 5:8317–8329. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wegrzyn J, Potla R, Chwae YJ, Sepuri NB,
Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, et
al: Function of mitochondrial Stat3 in cellular respiration.
Science. 323:793–797. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang R and Rincon M: Mitochondrial Stat3,
the Need for Design Thinking. Int J Biol Sci. 12:532–544. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gough DJ, Corlett A, Schlessinger K,
Wegrzyn J, Larner AC and Levy DE: Mitochondrial STAT3 supports
Ras-dependent oncogenic transformation. Science. 324:1713–1716.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu
D, Pan J, Pei D and Ding K: Identification of Niclosamide as a New
Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med
Chem Lett. 1:454–459. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen H, Yang Z, Ding C, Chu L, Zhang Y,
Terry K, Liu H, Shen Q and Zhou J: Discovery of O-Alkylamino
Tethered Niclosamide Derivatives as Potent and Orally Bioavailable
Anticancer Agents. ACS Med Chem Lett. 4:180–185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu PF, Lin CH, Kuo CH, Chen WW, Yeh DC,
Liao HW, Huang SM, Cheng AL and Lu YS: A pilot study of bevacizumab
combined with etoposide and cisplatin in breast cancer patients
with leptomeningeal carcinomatosis. BMC Cancer. 15:2992015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhou L, Xu S, Yin W, Lin Y, Du Y, Jiang Y,
Wang Y, Zhang J, Wu Z and Lu J: Weekly paclitaxel and cisplatin as
neoadjuvant chemotherapy with locally advanced breast cancer: A
prospective, single arm, phase II study. Oncotarget. 8:79305–79314.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Isakoff SJ, Mayer EL, He L, Traina TA,
Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, et al:
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum
Monotherapy With Biomarker Assessment in Metastatic Triple-Negative
Breast Cancer. J Clin Oncol. 33:1902–1909. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Silver DP, Richardson AL, Eklund AC, Wang
ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et
al: Efficacy of neoadjuvant Cisplatin in triple-negative breast
cancer. J Clin Oncol. 28:1145–1153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shah N, Mohammad AS, Saralkar P, Sprowls
SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE,
Pinti M, et al: Investigational chemotherapy and novel
pharmacokinetic mechanisms for the treatment of breast cancer brain
metastases. Pharmacol Res. 132:47–68. 2018. View Article : Google Scholar : PubMed/NCBI
|
